These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3709029)

  • 21. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.
    Zhou HH; Anthony LB; Wood AJ; Wilkinson GR
    Br J Clin Pharmacol; 1990 Sep; 30(3):471-5. PubMed ID: 2223426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in human urine by cyclodextrin micellar electrokinetic capillary chromatography: simple determination of a hydroxylation polymorphism in man.
    Desiderio C; Fanali S; Küpfer A; Thormann W
    Electrophoresis; 1994 Jan; 15(1):87-93. PubMed ID: 8143685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.
    Küpfer A; Patwardhan R; Ward S; Schenker S; Preisig R; Branch RA
    J Pharmacol Exp Ther; 1984 Jul; 230(1):28-33. PubMed ID: 6747829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
    Dahl ML; Llerena A; Bondesson U; Lindström L; Bertilsson L
    Br J Clin Pharmacol; 1994 Jan; 37(1):71-4. PubMed ID: 8148222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.
    Kobayashi K; Kogo M; Tani M; Shimada N; Ishizaki T; Numazawa S; Yoshida T; Yamamoto T; Kuroiwa Y; Chiba K
    Drug Metab Dispos; 2001 Jan; 29(1):36-40. PubMed ID: 11124227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotyping polymorphic drug metabolism in the French Caucasian population.
    Jacqz E; Dulac H; Mathieu H
    Eur J Clin Pharmacol; 1988; 35(2):167-71. PubMed ID: 3191936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
    Daniel HI; Edeki TI
    Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
    Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
    Küpfer A; Preisig R
    Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ; Villén T; Alm C; Bertilsson L
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
    Jurima M; Inaba T; Kadar D; Kalow W
    Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Family studies of mephenytoin hydroxylation deficiency.
    Inaba T; Jurima M; Kalow W
    Am J Hum Genet; 1986 May; 38(5):768-72. PubMed ID: 3717162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
    Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
    Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T; Jurima M; Nakano M; Kalow W
    Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
    Schellens JH; van der Wart JH; Breimer DD
    Br J Clin Pharmacol; 1990 Jun; 29(6):665-71. PubMed ID: 2378787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
    Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K
    Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans.
    Lim WH; Hooper WD
    Drug Metab Dispos; 1989; 17(2):212-7. PubMed ID: 2565213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereoselectivity of differential routes of drug metabolism: the fate of the enantiomers of [14C]mephenytoin in the dog.
    Küpfer A; Bircher J
    J Pharmacol Exp Ther; 1979 May; 209(2):190-5. PubMed ID: 438994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.